{"id":"W1478180867","doi":"10.1016/j.ejca.2015.06.072","title":"P0116 Updated clinical efficacy of the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in 411 patients with melanoma","year":2015,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; Monoclonal antibody; Melanoma; Antibody; Monoclonal; Oncology; Internal medicine; Cancer research; Immunotherapy; Immunology; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000783978,0.0003377491,0.0008668194,0.0006091415,0.0001953611,0.0008051493,0.0003697658,0.0004141278,0.001793279],"category_scores_gemma":[0.001391049,0.0001899648,0.0007779896,0.001025854,0.0001098592,0.0005388031,0.0001961185,0.0007055565,0.0005733173],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006906939,"about_ca_system_score_gemma":0.0004092293,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001721435,"about_ca_topic_score_gemma":0.003065493,"domain_scores_codex":[0.9996347,0.00007420313,0.00006490079,0.00007126578,0.0001202637,0.00003461801],"domain_scores_gemma":[0.9995258,0.0001262472,0.0001289106,0.00002634066,0.0001416473,0.00005100094],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.02326817,0.0006187491,0.3307748,0.002506859,0.00310729,0.001116971,0.0001457505,0.00257409,0.01367491,0.0004238262,0.02749787,0.5942908],"study_design_scores_gemma":[0.00335585,0.003515535,0.8963958,0.0005431895,0.00567884,0.00257418,0.00009788098,0.002977253,0.004601183,0.0005479638,0.07962923,0.00008307177],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8651418,0.09488432,0.0009821072,0.002541847,0.00091094,0.0002259347,0.01219117,0.0001433862,0.02297848],"genre_scores_gemma":[0.9607077,0.01917323,0.001439541,0.00145976,0.000902632,0.0001355208,0.01266598,0.00003178745,0.003483825],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001793279,"threshold_uncertainty_score":0.005999088,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03157796465360636,"score_gpt":0.3341233880962667,"score_spread":0.3025454234426604,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}